

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No 05-988-G; (EX03-089C-US))**

<b>In the Application of:</b>	)	
	)	
<b>Kadyk <i>et al.</i></b>	)	
	)	<b>Examiner: Cheu, Changhwa</b>
<b>Serial No.: 10/535,571</b>	)	
	)	<b>Group Art Unit: 1641</b>
<b>Filing Date: June 5, 2008</b>	)	
	)	<b>Confirmation No. 8822</b>
<b>For: MAPKs as Modifiers of the RAC, AXIN,</b>	)	
<b>and Beta-Catenin Pathways and Methods</b>	)	
<b>of Use</b>	)	

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the restriction requirement mailed on August 18, 2010, in the above-mentioned application. Applicants submit herewith a petition for a one month extension of time and the appropriate fee. It is believed that no further fee is due in connection with this filing. However, if a fee is due the Commissioner is authorized to charge our deposit account 13-2490.

With respect to the restriction requirement, Applicants hereby elect with traverse Group I, allegedly drawn to a method of identifying a candidate RAC, AXIN, and Beta-Catenin pathway agent, for prosecution on the merits. The claims readable thereon are claims 1-22.

Applicants note that the reference cited in the Restriction Requirement (MacDonald *et al.*, Nature Genetics, 29:143-152 (2001)), concerns a MAPKAP gene, which gene is structurally and functionally different from the MAPK and MINK genes used in the present invention.